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Abstract
Background: Opioids are prescribed in over 40% of patients with advanced cancer, but side effects occur frequently.
In this study we evaluated the development and treatment of opioid induced constipation (OIC), and OIC resolving
effect of methylnaltrexone for different opioid subtypes in daily clinical practice.
Methods: Patients with cancer using opioids were included in a retrospective chart analysis. Baseline characteristics,
data on opioid use, laxative use, and OIC were collected. Patients with OIC who were prescribed methylnaltrexone,
were included in a prospective observational trial (NCT01955213).
Results: Thirty-nine of 327 patients (pts) with cancer who were treated with opioids suffered from OIC (overall prevalence
12%; 95%-CI: 8–15%). The prevalence of OIC was similar in patients treated with oxycodone or fentanyl (12 of 81 pts. vs.
18 of 110 pts., RR 0.9; 95%CI 0.4–2.0). The morphine equivalent daily dose did not significantly differ between opioid
subtypes (fentanyl 89mg (IQR 60–180) vs. oxycodone 40mg (40–80), P = 0.231). Twenty-two individual patients (7%) were
admitted for OIC. Most effective laxatives in admitted patients were enemas, methylnaltrexone, or 4-l polyethylene-glycol
solution. In the prospective observational study, the effect of methylnaltrexone could be evaluated in 23 patients. Eleven
patients achieved the primary endpoint of ≥2 laxation responses out of the first four doses methylnaltrexone,
independent of opioid subtype.
Conclusions: OIC is a burdensome clinical problem independent of opioid subtype. Timely intensification of prophylactic
laxative treatment, especially when opioid doses increase, may help to prevent OIC. Clinically overt OIC requires a more
intensive laxative regimen with for example methylnaltrexone.
Trial registration: NCT01955213.
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Background
Over 40% of patients with advanced cancer need opioids at
some point during their disease trajectory [1, 2]. Opioids
may cause transient side effects such as nausea and drowsi-
ness [3]. A non-transient side effect of opioids is constipa-
tion [3]. Opioid induced constipation (OIC) is caused by
binding of opioids on the μ-receptor in the intestines,
leading to a decrease in peristaltic movements and a longer
transit time, allowing more water absorption from the stool
[4]. Differences in bio distribution and opioid receptor
binding profile result in varying incidence rates of OIC be-
tween different opioid subtypes [5]. While patients included
in trials are frequently prescribed single opioids, in daily
practice, combinations of different opioid subtypes are used
to tailor pain management and to optimize ease of use. Dif-
ferent laxatives are also prescribed in variable doses in line
with international guidelines advising to prescribe prophy-
lactic laxatives when opioids are being used [6, 7]. Most
used laxatives are osmotic agents e.g. polyethylene glycol
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(PEG) or magnesium oxide, and stimulant laxatives e.g.
bisacodyl. Adherence to the guidelines by physicians varies,
[8] and patients frequently stop using these prophylactic
laxatives due to diarrhea [9, 10]. Even more, other patient-
or treatment-related factors may cause constipation in
patients with cancer using opioids, such as reduced
fluid intake, or the use of 5-HT3 receptor antagonists
for chemotherapy induced nausea and vomiting. Real
life data on the prevalence of constipation, and more
specific opioid induced constipation, in patients with
cancer using opioids are scarce, [10–12] and compara-
tive trials evaluating different treatment options for
OIC have not yet been conducted.
The optimal treatment strategy for constipation de-
pends on its cause in an individual patient [6]. Various
strategies to treat OIC are available, including to start,
add, or increase the dose of laxatives; to admit patients
to the hospital for more intensive laxation treatment; to
decrease the dose of opioids (which is often not feasible);
to switch to another opioid subtype; or to use various
formulations of the μ-opioid receptor antagonist nalox-
one [7, 13]. Naloxone has been used in the past for opi-
oid induced constipation, but its use was associated with
opioid withdrawal and decreased pain relief [14]. As an
alternative methylnaltrexone, a quaternary amine of nal-
trexone that does not cross the blood-brain barrier, can
be prescribed. It can be used as a peripheral μ-receptor
antagonist which resolves OIC in 50% of patients, with-
out influencing the analgesic effect achieved by the cen-
tral effects of the opioid [14, 15].
In this study we evaluated the development and treat-
ment of opioid induced constipation in daily clinical prac-
tice, and the OIC resolving effect of methylnaltrexone for
different opioid subtypes. We performed a retrospective
chart review evaluating real-life data on opioid use and
the incidence of OIC in every day clinical practice, and the
effect of different treatment options for OIC. In addition,
a prospective observational trial was set up to study the ef-
fect of methylnaltrexone for OIC caused by different opi-
oid subtypes, in order to determine which patients could
benefit most from this treatment [5].
Methods
Retrospective chart review
Patients who were prescribed opioids by their oncologist at
an academic hospital and a large teaching hospital over a
six month period in 2014 were included in the retrospect-
ive study. Data concerning baseline characteristics, opioid
and laxative use, and the occurrence of OIC were extracted
from the patient charts. When multiple opioid prescrip-
tions were made in the study period, the prescription with
the highest oral morphine equivalent daily dose (MEDD)
was used for this analysis. Conversion rates from buprenor-
phine, fentanyl, subcutaneous morphine, oxycodone and
tramadol to oral morphine were 2.29, 2.4, 3, 3, and 0.2,
respectively [16]. For methadone conversion rates to oral
morphine were 4 for doses < 22.5mg, 6 for doses between
22.5 and 50mg, and 8 for doses > 50mg [16]. Notes on the
patient’s laxation pattern in the period between 30 days be-
fore and after the selected opioid prescription were ex-
tracted to evaluate if OIC had occurred. Admittances for
OIC were registered for the year prior to and following the
selected opioid prescription. In order not to miss admit-
tances with OIC as an underlying cause, we reviewed each
admission for the mentioning of (opioid-induced) constipa-
tion as a underlying cause for the reason of admission.
Constipation was defined as a reported change in laxation
frequency to less than 3 stools per week. Due to the retro-
spective nature of this part of the study, subjective compo-
nents to constipation could not be assessed. Constipation
was considered as opioid induced if this was made explicit
in the patient chart, and/or if there was no other major
contributing factor specified (e.g. dehydration, obstruction
of the GI-tract by a tumor or carcinomatous peritonitis, or
side effects from other drugs).
Sample size and statistics
Most of the presented data are descriptive. It was expected
that, even despite prophylactic laxative use, patients using
fentanyl would have a lower incidence rate of OIC than
patients using oxycodone [5]; 10% of the patients using
fentanyl would develop OIC, compared to 30% of the pa-
tients using oxycodone. In a population in which 40%
used fentanyl and 25% oxycodone, a study sample with at
least 120 patients using fentanyl and 80 using oxycodone
was needed to have 90% power to detect the hypothesized
difference in the incidence of OIC between fentanyl and
oxycodone (P < 0.05 was considered statistically signifi-
cant). Descriptive data are presented by their mean or me-
dian, and SD or inter quartile range (IQR). Comparisons
were made with a Pearson’s Χ2 test or Mann-Whitney U
test, as considered appropriate. For assessing the effect of
multiple factors, multiple logistic regression was used.
Prospective observational study
The methods of the observational trial to determine the
differences in the effect of methylnaltrexone on OIC in-
duced by different opioid subtypes are published else-
where [5]. Briefly summarized, patients with OIC
caused by morphine, oxycodone, or fentanyl, without
contra-indications for methylnaltrexone, received a
14-day treatment with methylnaltrexone subcutane-
ously (SQ) every other day. In this period a laxation
diary was kept to monitor the effect of methylnaltrex-
one. The Bowel Function Index questionnaire (BFI)
[17] was completed at the start and end of this treat-
ment period. We aimed to include 78 patients in the
oxycodone group, 78 patients in the morphine group
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and 39 patients in the fentanyl group. This study was
approved by the Medical research Ethics Committee of
the VU University medical center and performed in
accordance with the Helsinki Declaration of the World
Medical Association.
BFI questionaire
The BFI consists of three questions about symptoms
of constipation experienced during the past week. An-
swers to these questions are rated on a scale from 0
to 100 and the final score is calculated by the mean
of the three answers. A decrease of 12 points or more
between start and end of the study is thought to be a
clinically significant response [5, 17].
Software for data storage and analysis
Data of both studies were anonymized and stored in the
web based database system Open Clinica (Open Clinica
version 3.3). Statistical analyses were performed with
IBM SPSS version 22.0 (IBM, Armonk, NY, USA).
Results
Patient characteristics
Three hundred twenty seven patients were included in
the retrospective analysis. Characteristics of these pa-
tients are presented in Table 1. Fentanyl (N = 131, 40%)
and oxycodone (N = 90, 28%) were the most frequently
prescribed opioid subtypes. Ninety-four patients (29%)
did not use a maintenance opioid, only rescue doses.
Tumor types, treatment intention (curative or pallia-
tive), intake failure (especially reduced fluid intake),
and abdominal innervation problems (paralysis of the
intestines) between the fentanyl and oxycodone group
were significantly different. For fentanyl maintenance
treatment continuous-release patches were used. These
were mostly prescribed for patients treated with
chemo-radiotherapy for head and neck cancer, which
explains most differences in characteristics between the
treatment groups. When correcting for this tumor type,
only intake failure remained statistically significant
more frequent in the patients using fentanyl patches
(28/95 vs. 8/85 in the oxycodone group, P = 0.001), and
abdominal innervation problems were more frequent in
the oxycodone group (7/85 vs. 1/95 in the fentanyl
group, P = 0.017).
Sixty percent of the patients used concurrent laxatives,
mostly a polyethylene-glycol solution (PEG), magnesium
oxide, and/or enema’s (55, 7, and 6% respectively, Table 2).
Thirty-one patients (9%) used two or more types of laxa-
tives. There were no statistically significant differences in
the number of patients using a specific laxative, nor in the
dose of laxatives, between patients using fentanyl or oxy-
codone, except for the dose of magnesium which was
higher in patients using oxycodone (N = 5) than in
patients using fentanyl (N = 13) (median 6 vs. 3 tablets per
day, P = 0.033).
When converted to oral morphine equivalent daily dose
(MEDD), the median dose of regularly taken opioids was
60mg (IQR 29–120). Two-hundred-and-ninety-one pa-
tients (89%) were prescribed rescue opioids, mostly
short-acting oxycodone (n = 185, 57%).
Opioid induced constipation
For 257 patients (79%) the attending physician made a
note in the patient’s chart on their laxation pattern.
Sixty-eight patients (21%) were constipated, of whom 39
(12%) were considered to be constipated due to opioids
(Table 3). OIC was equally prevalent in patients treated
with oxycodone or fentanyl (12 of 81 pts. vs. 18 of 110
pts., RR 0.9, 95% CI 0.4–2.0). Although there was a
statistically significant difference in the oral morphine
equivalent daily dose (MEDD) of regularly taken opioids
between patients using fentanyl and oxycodone at opioid
prescription (fentanyl MEDD 60mg (IQR 29–120), oxy-
codone MEDD 40mg (IQR 40–80), P = 0.006), the
difference in the MEDD at diagnosis of OIC was not sta-
tistically significant (fentanyl 89 mg (IQR 60–180) vs.
oxycodone 40 mg (IQR 40–80), P = 0.231). When analyz-
ing the effects of opioid subtypes fentanyl and oxy-
codone and MEDD on OIC in a multiple logistic
analysis, none showed statistical significance (OR for the
risk at OIC for MEDD 0.997 (95% CI 0.990–1.005); for
fentanyl 1.310 (95% CI 0.351–4.892); and for oxycodone
4.086 (95% CI 0.630–26.495)). Also, no difference in
OIC was found between patients using oxycodone or
fentanyl as rescue opioid (13% vs. 9%, P = 0.554).
In the majority of the patients with OIC, the opioid
dose remained stable (N = 14) or was increased (N = 14).
In 32 patients diagnosed with OIC (82%) the laxative
treatment was adjusted, mostly by prescribing a new
laxative (N = 20). The main reason not to alter the laxa-
tive treatment while a patient was diagnosed with OIC,
or to even stop the laxative treatment, was that the pa-
tient had entered the terminal phase and was not able to
take oral medication anymore (N = 6).
Admission for OIC
Twenty-two individual patients (7%) were admitted to
the hospital for OIC (Table 3). The median MEDD at
admission was 70mg (IQR 40–180). Eleven patients
used fentanyl, with a median MEDD of 180 mg (IQR
60–180). Five patients used oxycodone, with a median
MEDD of 60mg (IQR 40–140). The difference between
the doses of fentanyl and oxycodone at admission was
not statistically significant (P = 0.145). The opioid pre-
scription was adjusted because of OIC in 4 of the 22
patients; in one patient the dose was lowered, in three
patients an opioid rotation was performed.
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Table 1 Patient characteristics - retrospective chart review
Total
N = 327 (%)
Fentanyl Maintenance
N = 131 (%)
Oxycodon maintenance
N = 90 (%)
P (fentanyl
vs. oxycodone)
Age mean (SD) 63 (12) 64 (11) 63 (12) 0,368
Sex Male 146 (45) 64 (49) 41 (46)
Female 181 (55) 67 (51) 49 (54) 0,629
Cancer type Gastro-intestinal 110 (34) 43 (33) 26 (29)
Breast 54 (17) 13 (10) 19 (21)
Genito-urethral 62 (19) 23 (20) 26 (29)
Skin 15 (5) 7 (5) 5 (6)
Lung 1 (0) 1 (1) 0 (0)
Head&Neck 53 (16) 33 (25) 5 (6)
Brain 3 (1) 1 (1) 0 (0)
Sarcoma 6 (2) 2 (2) 2 (2)
Other 23 (7) 5 (4) 7 (8) 0,005*
Treatment intention Curative 71 (22) 37 (28) 9 (10)
Palliative 256 (78) 94 (72) 81 (90) 0,001*
Current Treatment Follow-up 7 (2) 3 (2) 1 (1)
Watchfull waiting 22 (7) 7 (5) 5 (6)
Chemotherapy 90 (28) 32 (24) 28 (31)
Radiotherapy 15 (5) 7 (5) 5 (6)
Chemoradiotherapy 38 (12) 25 (19) 3 (3)
Targetted therapy 51 (16) 17 (13) 17 (19)
Best supportive care 81 (25) 33 (25) 24 (27)
Other 23 (7) 7 (5) 7 (8) 0,032*
ECOG performance status 0 14 (4) 3 (2) 7 (8)
1 110 (34) 40 (31) 36 (40)
2 67 (21) 22 (17) 20 (22)
3 29 (9) 14 (11) 11 (12)
4 17 (5) 6 (5) 1 (1)
Unknown 90 (28) 46 (35) 15 (17) 0,264
Contributing factors Peritoneal tumor depositions 52 (16) 21 (16) 13 (14) 0,748
Intestinal metastasis 19 (6) 8 (6) 3 (3) 0,352
Involvement of other abdominal organs 115 (35) 45 (34) 34 (38) 0,602
Hypercalcemia 21 (6) 13 (10) 6 (7) 0,239
Reduced mobility 116 (36) 47 (36) 34 (38) 0,773
Intake failure 71 (22) 41 (31) 9 (10) < 0,001*
Constipating co-medication 75 (23) 30 (23) 18 (20) 0,607
Abdominal innervation problems 11 (3) 1 (1) 7 (8) 0,006*
Bowel disease 4 (1) 1 (1) 1 (1) 0,789
Depression 3 (1) 2 (2) 0 (0) 0,239
Pain Scorea NRS 0–10, mean (SD) 4,0 (6,0) 4,0 (5,0) 5,0 (6,5) 0,948
Opioid dosesb Maintenance dose, median (IQR) 60 (29–120) 60 (29–120) 40 (40–80) 0,006*
Rescue dosec 20 (3–40) 23 (10–50) 20 (0–40) 0,259
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Patients admitted for OIC were mostly treated with
enema’s (N = 16) and a 4-l polyethylene glycol solution
(N = 11). Complete resolution of constipation was seen
with enema’s (N = 5/16), methylnaltrexone SQ (N = 2/5)
and with a 4-l polyethylene glycol solution (N = 2/2).
Effect of SQ methylnaltrexone in different opioid
subtypes
Twenty-six patients were included in the methylnal-
trexone trial between July 2012 and December 2015.
Baseline characteristics of the included patients are
presented in Table 4. Sixteen patients used oxycodone,
eight fentanyl and two morphine. Three patients were
lost to follow-up because the laxation diary was not
returned (two in the fentanyl group, one in the
oxycodone group). Of the 23 patients who returned re-
sponse data of at least one dose of SQ methylnaltrex-
one, 11 met the primary endpoint of at least 2 laxation
responses out of the first 4 doses. These were 8 pa-
tients in the oxycodone group (8 of 15 pts., 53%), 2 in
the fentanyl group (2 of 6 pts., 33%) and 1 in the mor-
phine group (1 of 2 pts., 50%). Reasons to prematurely
stop SQ methylnaltrexone treatment were: per patient
request (N = 4), adverse events (N = 2: 1 diarrhea, 1
abdominal pain), intercurrent illness (N = 1), death due
to disease progression (N = 1), and unknown (N = 1).
Bowel function index (BFI)
Fourteen patients completed the BFI questionnaire on
day 0 and 14 (2 in the fentanyl group, 1 in the morphine
group, and 11 in the oxycodone group). The median
change between start and end of study was − 5.8 points
(IQR − 42.1 to 13.8), where a 12-point decline was previ-
ously defined as a clinically significant improvement.
There were no statistically significant differences in BFI
changes between patients who did or did not meet the
studies primary endpoint (median ΔBFI 0.8 vs. -6.7
respectively, P = 0.573).
Table 1 Patient characteristics - retrospective chart review (Continued)
Total
N = 327 (%)
Fentanyl Maintenance
N = 131 (%)
Oxycodon maintenance
N = 90 (%)
P (fentanyl
vs. oxycodone)
Rescue opioid subtypes No rescue opioid 36 (11) 9 (7) 6 (7)
Buprenorfine 14 (4) 0 (0) 0 (0)
Fentanyl 24 (7) 17 (13) 3 (3)
Methadon 2 (1) 0 (0) 0 (0)
Morphine 57 (17) 34 (26) 5 (6)
Oxycodon 185 (57) 71 (54) 76 (84)
Tramadol 5 (2) 0 (0) 0 (0)
Other 4 (1) 0 (0) 0 (0) < 0,001*
* marks the statistically significant results
aPain score at a numerical rating scale (NRS) from 0 to 10 at the moment the opioid was prescribed (N = 115)
bOral morphine equivalent daily doses (MEDD) at the moment of opioid prescription
cRescue opioid doses, calculated for patients with a known rescue frequency (total N = 135, fentanyl N = 64, oxycodone N = 30)
Table 2 Laxative use at opioid prescription
Total
N = 327 (%)
Fentanyl
maintenance
N = 131 (%)
Oxycodone
maintenance
N = 90 (%)
P (fentanyl vs.
oxycodone
group)
Any laxative 195 (60) 88 (67) 63 (70) 0,657
Polyethylene
glycol solution
181 (55) 78 (60) 60 (67) 0,283
PEG dose,
mediana
1 1 1
Magnesium 23 (7) 13 (10) 5 (6) 0,243
Magnesium
dose,
medianb
3 3 6
Bisacodyl 3 (1) 3 (2) 0 (0) 0,148
Bisacodyl
dose,
medianc
1 1 .
Lactulose 7 (2) 3 (2) 2 (2) 0,973
Lactulose
dose,
mediand
1 1 2
Enema’s 18 (6) 5 (4) 7 (8) 0,202
Enema
frequency,
mediane
1 1 1
Other 3 (1) 2 0 (0) 0,239
aNumber of polyethylene glycol sachets per day. Sachet à 13,7 g containing
polyethylene glycol and elektrolytes (potassiumchloride, sodiumchloride,
sodium hydrogen carbonate). Inter quartile range (IQR) total group: 1–2;
fentanyl group: 1–2; oxycodone group: 1–2
bNumber of magnesium oxide tablets à 500 mg per day. IQR total group: 2–6;
fentanyl group 2–3; oxycodone group: 4–6
cNumber of bisacodyl tablets à 5mg per day. Range total group: 1–1; fentanyl
group: 1–1; oxycodone group: not applicable
dNumber of lactulose doses per day. One dose equals 15 ml of lactulose 670
mg/ml. Range total group: 0–2; fentanyl group: 0–2; oxycodone group: 0–2
eNumber of enema’s per day, usually a sodium phosphate enema of 133 ml
containing 31,8 mg sodium acid phosphate and 139,1 mg sodium
dihydrogenphosphate per ml. IQR total group: 0,5–1; fentanyl group: 0–1;
oxycodonde group: 0,5–1
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Discussion
To our knowledge, this is the first study in which the
frequency of OIC in real life in an unselected population
of patients with cancer is being evaluated. In a study by
Wirz et al. [10] and a survey by Bell et al. [12] among
long term opioid users with a wide range of diseases
data on this subject were limited to secondary endpoints
in clinical trials. Bell et al. found that 81% of the 322
included patients (a selection from 130,293 originally
invited patients) suffered from constipation despite
Table 3 Opioid Induced Constipation
Opioid
maintenance
typea
N= Note on laxation
pattern
N (%)b,c
Morphine
dose (MEDD)d
median (IQR)
ConstipationeN (%) MEDDd,f
median (IQR)
Opioid Induced
Constipationg,h
N (%)
MEDDi
median (IQR)
Admission
for OICj
N (%)k
MEDDl
median (IQR)
No
maintenance
opioid
94 77 (82) 0 (0) 12 (13) 0 (0) 1 (1) 0 (0) 1 (1) 0
Buprenorfine 16 16 (100) 105 (31–180) 5 (31) 24 (17–98) 3 (19) 30 (17–120)m 2 (13) 54 (17–90)o
Fentanyl 110 86 (78) 89 (60–150) 25 (23) 89 (60–180) 18 (16) 89 (60–180) 11 (10) 180 (60–180)
Methadon 3 2 (67) 60 (60–240)m 2 (67) 120 (60–240)m 1 (33) 240 (0) 0 (0) n.a.
Morphine 5 3 (60) 60 (40–96) 3 (60) 60 (40–96)m 2 (40) 68 (40–96)m 3 (60) 60 (40–80)o
Oxycodon 81 64 (79) 40 (40–80) 19 (23) 40 (40–80) 12 (15) 40 (40–80) 5 (6) 60 (40–140)
Tramadol 14 7 (50) 30 (20–40) 1 (7) 20 (0) 1 (7) 20 (0) 0 (0) n.a.
Other 4 2 (50) 7 (5–10)m 1 (25) n.a.n 1 (25) n.a.n 0 (0) n.a.
Total 327 257 (79) 60 (40–120) 68 (21) 60 (40–120) 39 (12) 60 (40–120) 22 (7) 70 (40–180)
aOpioid maintenance type at note on laxation pattern or at prescription (if no note was found in the patient records)
bNumber of patients in each subtype for whom a note was made at their laxation pattern, P = 0.931
cPercentage of patients with a note on their laxation pattern for each opioid subtype
dOral Morphine Equivalent Daily Dose (MEDD) in milligrams
eNumber of patients with a diagnosis of constipation in each opioid subtype, P = 0.030
fThe difference between the fentanyl group and the oxycodone subgroup was statistically significant, P = 0.043
gNumber of patients with a diagnosis of opioid induced constipation (OIC), P = 0.006
hPercentage of patients with a diagnosis of opioid induced constipation for each opioid subtype
iThe difference in MEDD of patients using fentanyl or oxycodone was not statistically significant, P = 0.231
jOpioid subtype the papient was using at admission for OIC
kPercentage of patients admitted for OIC relative to the number of patients using this opioid subtype at the moment of the opioid prescription included in this analysis
lOral Morphine Equivalent Daily Dose (MEDD) at the moment of admission for OIC; IQR = inter quartile range
mRange instead of interquartile range, due to low number of patients using this opioid subtype
nThe MEDD could not be calculated because the conversion rate for this opioid subtype is unknown
oRange in stead of inter quartile range, due to the low number of patients using this opioid subtype
Table 4 Patient characteristics methylnaltrexone trial
Total
N = 26
Oxycodone group
N = 16
Fentanyl group
N = 8
Morphine group
N = 2
Age mean (SD) 59 (13) 58 (10) 58 (18) 62 (18)
Sex Male 11 9 2 0
Female 15 7 6 2
Treatment setting Hospital 20 11 7 2
Ambulant 6 5 1 0
Cancer Type Gastro-intestinal 9 6 3 0
Breast 6 3 2 1
Genito-urethral 6 5 1 0
Other 5 2 2 1
Concomitant laxatives PEG 19 12 5 2
Magnesiumoxide 7 4 3 0
Other 3 3 0 0
Patients using > 1 laxative 4 3 1 0
Morphine equivalent daily dose median (range) 80 (40–540) 80 (40–160) 120 (60–240) 525 (510–540)
PEG polyethylene glycol solution
Neefjes et al. BMC Palliative Care           (2019) 18:31 Page 6 of 9
laxative use, but it remained unclear to what extent the
constipation was opioid induced. Wirz et al. performed a
prospective observational study in ambulatory patients
with cancer referred to the pain clinic. This study re-
vealed a 5,7% incidence rate of constipation in a highly
selected group of ambulatory patients using stable opioid
doses > 28 days, without the need for break-through opi-
oids, and who were not undergoing chemo- or radio-
therapy treatment [10].
In our retrospective chart review 21% of the 327 pa-
tients with cancer using opioids suffered from constipa-
tion, which was opioid induced in 12% (39 patients).
Eighty-seven percent of these patients (34 of 39 pts) de-
veloped OIC despite laxative use. The doses of prophy-
lactic laxatives in this study group were relatively low
(e.g. a single polyethylene glycol solution once per day).
Therefore, intensification of the prophylactic laxative
treatment, especially when the opioid dose increases,
might help to reduce the number of admissions for OIC.
However, when a patient is admitted for OIC, dose in-
creases of these laxatives do not seem to resolve the
problem. At this point more intensive treatments, such
as a 4-l polyethylene glycol solution, enema’s, and pos-
sibly SQ methylnaltrexone, are more effective.
Our hypothesis that OIC occurs more often in patients
using oxycodone than in patients using fentanyl, was not
confirmed. Although the median MEDD of patients
using fentanyl was more than twice the median MEDD
for the patients using oxycodone at the moment patients
were diagnosed with OIC, this difference was not statis-
tically significant. Therefore, we cannot conclude that
oxycodone is more constipating than fentanyl. It might
be that the large proportion of patients using oxycodone
as rescue opioid next to fentanyl as maintenance opioid
has influenced the results, but there were no statistically
significant differences found between patients using dif-
ferent subtypes of rescue opioids. This mixture of opioid
subtypes reflects real daily practice, which is one of the
strengths of this study. Our data complement the find-
ings from opioid and laxative registration studies by pro-
viding valuable information on treatment practices and
patient characteristics among unselected patients. This
information is necessary to guide treatment decisions
and for reimbursement and payment decisions.
The results of the chart review are limited to the notes
that were made in the patient charts and the hospitals
electronic prescription systems. Therefore it is possible
that some cases of OIC were missed. Also, data on the
actual opioid intake were not available. Based on the low
number of records for pain scores noted at the moment
of opioid prescription (N = 115 of 327 pts), and the low
number of records of the frequency of rescue opioid use
(N = 135 of 327 pts), there might be a gap between what
is discussed by the patient and the physician, and what
is noted in the patient’s chart. Other measures to pre-
vent OIC, such as life-style advises, that were discussed
with the patient, were not assessed in this study because
they were often not recorded in the patient’s chart, and
compliance to these advises could not be assessed. An-
other limitation is that most physicians only diagnosed
constipation based on a reduced stool frequency. More
subjective components of constipation, such as a feeling
of abdominal distension, or straining to pass the stool,
were given less attention.
The prospective observational study evaluating the ef-
ficacy of SQ methylnaltrexone in different opioid sub-
types did not reach the anticipated sample size. The
results of this trial therefore do not have enough power
to draw any conclusions with regard to the hypothesis
that patients using fentanyl would have a lower response
rate to SQ methylnaltrexone than patients using oxy-
codone or morphine. The low inclusion rate was due to
the significantly lower than expected prevalence of OIC,
and the fact that many patients used a combination of
different opioid subtypes, which was an exclusion criter-
ion for the study. Contra-indications for SQ methylnal-
trexone use were rare. Only 10 patients received all
seven methylnaltrexone administrations. The others
stopped treatment prematurely due to side effects or the
lack of efficacy. There were also a number of patients
who requested to stop treatment even though it was ef-
fective. These patients did not suffer from grade 3 side
effects, but generally reported a feeling of unease during
the first hours after methylnaltrexone administration
that may be interpreted as mild side effects or mild opi-
oid withdrawal symptoms. These observed side effects
are important for designing possible future studies look-
ing into the effect of μ-opioid receptor blockade on
tumor progression [18].
For clinical practice the results of this study indicate
that it is important to ask patients who use opioids regu-
larly about their laxation pattern, and to adjust the
prophylactic laxative prescription with increasing opioid
doses. Thereby the development of OIC could possibly
be prevented or managed in an ambulant setting, instead
of requiring a hospital admission.
Conclusions
In this real-life cohort of patients with cancer, OIC was
encountered in 12 % of the patients using opioids and
lead to a hospital admission in 7 %. Timely intensifica-
tion of prophylactic laxative treatment, especially when
the opioid dose increases, might help to further reduce
the number of patients with cancer suffering from OIC
and may help to prevent hospital admission. Treatment
of OIC, once it has developed, requires a more intensive
laxative regimen with for example SQ methylnaltrexone,
independent of opioid subtype.
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